Objective: This study assessed the efficacy and safety of armodafinil, the longer half-life enantiomer of modafinil, for the treatment of excessive sleepiness in patients with narcolepsy. Research design and methods: This was a multicenter double-blind study with 196 patients (aged 18-65 years) randomized to receive armodafinil 150 mg (n = 65), armodafinil 250 mg (n = 67), or placebo (n = 64) once daily for 12 weeks. Main outcome measures: Efficacy was assessed using the Maintenance of Wakefulness Test (MWT) (six 20-min subtests across the day), the Clinical Global Impression of Change (CGI-C), subjective measures of sleepiness (Epworth Sleepiness Scale), patient diaries, and evaluations of cognitive performance (Cognitive Drug Research) an...
International audienceStudy objectives: To assess the efficacy and safety of FT218, a novel once-nig...
Item does not contain fulltextBACKGROUND: Early recovery of patients following sedation/analgesia an...
Modafinil is a novel wake-promoting agent approved by the FDA ameliorating excessive daytime sleepin...
Study Objectives: Armodafinil is a wakefulness-promoting medication. Its efficacy and tolerability h...
SummaryObjectiveArmodafinil is the R-enantiomer of racemic modafinil and has a significantly longer ...
Excessive sleepiness is the most concerned and debilitating symptoms suffered by patients with vario...
Objectives: To assess the efficacy and safety of modafinil for improving wakefulness in narcolepsy p...
OBJECTIVE: The objective of this selective EBM review is to determine whether or not modafinil (Prov...
Objective: Solriamfetol (JZP-110) is a selective dopamine and norepinephrine reuptake inhibitor with...
Abstract: Excessive sleepiness (ES) is responsible for signifi cant morbidity and mortality due to i...
This thesis aims to evaluate the safety and efficacy of wakefulness promoters modafinil and armodafi...
OBJECTIVE: To assess the effects of three narcolepsy treatment modalities on sleep stage shifts asso...
Background: Narcolepsy is characterised by excessive daytime sleepiness (EDS) and cataplexy. Histami...
International audienceAbstract Study Objectives To evaluate long-term safety and maintenance of effi...
Objective: To examine the impact of night-shift duration (\u3c= 9 hours or \u3e9 hours) on efficacy ...
International audienceStudy objectives: To assess the efficacy and safety of FT218, a novel once-nig...
Item does not contain fulltextBACKGROUND: Early recovery of patients following sedation/analgesia an...
Modafinil is a novel wake-promoting agent approved by the FDA ameliorating excessive daytime sleepin...
Study Objectives: Armodafinil is a wakefulness-promoting medication. Its efficacy and tolerability h...
SummaryObjectiveArmodafinil is the R-enantiomer of racemic modafinil and has a significantly longer ...
Excessive sleepiness is the most concerned and debilitating symptoms suffered by patients with vario...
Objectives: To assess the efficacy and safety of modafinil for improving wakefulness in narcolepsy p...
OBJECTIVE: The objective of this selective EBM review is to determine whether or not modafinil (Prov...
Objective: Solriamfetol (JZP-110) is a selective dopamine and norepinephrine reuptake inhibitor with...
Abstract: Excessive sleepiness (ES) is responsible for signifi cant morbidity and mortality due to i...
This thesis aims to evaluate the safety and efficacy of wakefulness promoters modafinil and armodafi...
OBJECTIVE: To assess the effects of three narcolepsy treatment modalities on sleep stage shifts asso...
Background: Narcolepsy is characterised by excessive daytime sleepiness (EDS) and cataplexy. Histami...
International audienceAbstract Study Objectives To evaluate long-term safety and maintenance of effi...
Objective: To examine the impact of night-shift duration (\u3c= 9 hours or \u3e9 hours) on efficacy ...
International audienceStudy objectives: To assess the efficacy and safety of FT218, a novel once-nig...
Item does not contain fulltextBACKGROUND: Early recovery of patients following sedation/analgesia an...
Modafinil is a novel wake-promoting agent approved by the FDA ameliorating excessive daytime sleepin...